カテゴリー： Global Markets Direct, 医療/バイオ

ソマトスタチン受容体タイプ2治療薬市場：パイプラインレビュー（2019年下半期）

【英語タイトル】Somatostatin Receptor Type 2 - Pipeline Review, H2 2019

Global Markets Directが出版した調査資料（GDATA20MY0344）・商品コード：GDATA20MY0344
・発行会社（調査会社）：Global Markets Direct
・発行日：2019年12月27日
・ページ数：71
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：製薬
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,500 ⇒換算￥371,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD7,000 ⇒換算￥742,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD10,500 ⇒換算￥1,113,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
【レポートの概要】

Somatostatin Receptor Type 2 – Pipeline Review, H2 2019
Summary

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) pipeline Target constitutes close to 13 molecules. The latest report Somatostatin Receptor Type 2 – Pipeline Review, H2 2019, outlays comprehensive information on the Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Somatostatin receptor type 2 is a protein that encoded by the SSTR2 gene. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. SSTR2 is expressed in highest levels in cerebrum and kidney. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 6 and 2 respectively. Report covers products from therapy areas Hormonal Disorders, Oncology, Metabolic Disorders, Gastrointestinal, Genetic Disorders and Undisclosed which include indications Acromegaly, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion (Cushing Disease), Pituitary Tumor, Gastric Motility Disorder, Hypoglycemia, Ileus (Intestinal Obstruction), Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma (Glomus Jugulare Tumor), Pheochromocytoma, Polycystic Kidney Disease, Type 2 Diabetes and Unspecified.

Furthermore, this report also reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
- The report reviews Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 2 (SRIF1 or SSTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Overview
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Companies Involved in Therapeutics Development
Amryt Pharma Plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Enteris BioPharma Inc
GlyTech Inc
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Tiburio Therapeutics Inc
Zucara Therapeutics Inc
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Drug Profiles
AP-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-00808 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-01941 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Edotreotide Labeled Yttrium 90 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide acetate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide SR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR2 for Type 2 Diabetes – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBR-760 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide ER – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide IR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZT-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Dormant Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Discontinued Products
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) – Product Development Milestones
Featured News & Press Releases
Oct 31, 2019: Ipsen presents data on Somatuline Autogel at ISPOR Europe 2019
Jul 12, 2019: Zucara Therapeutics secures grant from GlycoNet to expand and validate their Drug Therapy Model for Type 1 Diabetes to Type 2 Diabetes
Jun 24, 2019: Ipsen announces U.S. FDA approval for newly designed pre-filled syringe for Somatuline Depot (lanreotide)
May 24, 2019: New investigational clinical data for Ipsens oncology products including lanreotide acetate in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting
May 24, 2019: Ipsen to present on Somatuline at 2019 ASCO Annual Meeting
May 21, 2019: Crinetics Pharmaceuticals initiates phase 1 study of CRN01941 for the treatment of neuroendocrine tumors
Mar 19, 2019: Crinetics Pharmaceuticals doses first patients in phase 2 clinical trials of CRN00808 for acromegaly
Mar 14, 2019: Crinetics Pharmaceuticals announces presentation on drug candidate CRN-00808 at ENDO2019
Mar 06, 2019: Ipsen to present improvements to Somatuline Autogel pre-filled syringe at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference
Feb 28, 2019: Ipsen to present new data on enhancement of patient care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference
Oct 12, 2018: Ipsen to present data on Lanreotide at ESMO 2018
Oct 05, 2018: Ipsen presents data on Somatuline depot at the North American Neuroendocrine Tumor Society (NANETS) Annual Symposium
Jun 21, 2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Acromegaly
Mar 12, 2018: Crinetics Pharmaceuticals Announces Upcoming Presentation on Acromegaly Drug Candiadate CRN00808 at ENDO 2018
Feb 13, 2018: Health Canada approves Ipsen Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amryt Pharma Plc, H2 2019
Pipeline by Crinetics Pharmaceuticals Inc, H2 2019
Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019
Pipeline by Enteris BioPharma Inc, H2 2019
Pipeline by GlyTech Inc, H2 2019
Pipeline by Ipsen SA, H2 2019
Pipeline by Progenics Pharmaceuticals Inc, H2 2019
Pipeline by Strongbridge Biopharma plc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Tiburio Therapeutics Inc, H2 2019
Pipeline by Zucara Therapeutics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

【掲載企業】

Amryt Pharma Plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Enteris BioPharma Inc
GlyTech Inc
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Tiburio Therapeutics Inc
Zucara Therapeutics Inc

★調査レポート[ソマトスタチン受容体タイプ2治療薬市場：パイプラインレビュー（2019年下半期）] (コード：GDATA20MY0344)販売に関する免責事項を必ずご確認ください。
★調査レポート[ソマトスタチン受容体タイプ2治療薬市場：パイプラインレビュー（2019年下半期）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 低血糖治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0172 / Global Markets Direct / 2019年11月29日 / ...Hypoglycemia - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Pipeline Review, H2 2019, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape. Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoglycemia...
  • アリール炭化水素受容体治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0304 / Global Markets Direct / 2019年12月27日 / ...Aryl Hydrocarbon Receptor - Pipeline Review, H2 2019 Summary Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 26 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Aryl Hydrocarbon Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Aryl Hydrocarbon...
  • リゾホスファチジン酸受容体1治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0431 / Global Markets Direct / 2019年12月27日 / ...Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2019 Summary According to the recently published report 'Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2019'; Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) pipeline Target constitutes close to 7 molecules. Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA) receptor belongs to a group known as EDG receptors. EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, and smooth muscle contraction, inhibition...
  • 受容体チロシンプロテインキナーゼERBB4治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0334 / Global Markets Direct / 2019年12月27日 / ...Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H2 2019 Summary According to the recently published report 'Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H2 2019'; Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c...
  • N-ホルミルペプチド受容体2治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0351 / Global Markets Direct / 2019年12月27日 / ...N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019 Summary According to the recently published report 'N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019'; N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) pipeline Target constitutes close to 8 molecules. N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - N-formyl peptide receptor 2 (FPR2) is a G-protein coupled receptor (GPCR) encoded by the FPR2 gene and is activated...
  • ソマトスタチン受容体タイプ4治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0414 / Global Markets Direct / 2019年12月27日 / ...Somatostatin Receptor Type 4 - Pipeline Review, H2 2019 Summary According to the recently published report 'Somatostatin Receptor Type 4 - Pipeline Review, H2 2019'; Somatostatin Receptor Type 4 (SSTR4) pipeline Target constitutes close to 5 molecules. Somatostatin Receptor Type 4 (SSTR4) - Somatostatin receptor type 4 is a protein encoded by the SSTR4 gene. The activity of receptor is mediated by G proteins which inhibits adenylyl cyclase. It mediates antiproliferative action of somatostatin in tumor cells. It is functionally coupled to inhibition of adenylate cyclase and activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade. The report...
  • 麻酔効果治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0093 / Global Markets Direct / 2019年11月25日 / ...Anesthetic Effect - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H2 2019, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape. Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central...
  • グルコース依存性インスリン分泌性受容体治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0427 / Global Markets Direct / 2019年12月27日 / ...Glucose Dependent Insulinotropic Receptor - Pipeline Review, H2 2019 Summary Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - G protein-coupled receptor 119 also known as GPR119 is a G protein-coupled receptor that is encoded by the GPR119 gene. GPR119 is expressed at high concentrations in the pancreas and gastrointestinal tract. GPR119 regulates incretin and insulin hormone secretion. Activation of GPR119 receptor causes a reduction in food intake and weight gain. This target is a potential drug target in treatments for obesity and diabetes. Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) pipeline Target...
  • 軽度認知障害治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0101 / Global Markets Direct / 2019年11月25日 / ...Mild Cognitive Impairment - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2019, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape. Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol....
  • 糖尿病性末梢神経障害治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0173 / Global Markets Direct / 2019年11月29日 / ...Diabetic Peripheral Neuropathy - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H2 2019, provides an overview of the Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline landscape. "Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legsand feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain ordiscomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tonein the feet and lower legs, loss of balance,...

    • ◆H&Iグローバルリサーチのお客様（例）◆